Priovant Advances Brepocitinib into Phase 3 for Cutaneous Sarcoidosis
Event summary
- First patients enrolled in Phase 3 BEACON+ study of brepocitinib for cutaneous sarcoidosis (CS).
- Study will enroll ~140 patients across ~70 global sites, with topline data expected in 2028.
- Brepocitinib previously received FDA Breakthrough Therapy Designation for CS after positive Phase 2 results.
- Priovant's NDA for brepocitinib in dermatomyositis under Priority Review, with PDUFA date later this quarter.
The big picture
Priovant is advancing brepocitinib as a potential cornerstone therapy for multiple high-burden autoimmune diseases with limited treatment options. The Phase 3 enrollment in cutaneous sarcoidosis follows positive Phase 2 data and Breakthrough Therapy Designation, while the upcoming dermatomyositis NDA decision could validate the drug's broader clinical utility. Success across these indications would position Priovant as a key player in rare inflammatory disease therapeutics.
What we're watching
- Regulatory Momentum
- Whether Priovant can secure FDA approval for brepocitinib in dermatomyositis by September 2026, setting the stage for additional indications.
- Clinical Execution
- The pace at which BEACON+ enrolls patients and whether Phase 3 results replicate Phase 2 efficacy in cutaneous sarcoidosis.
- Pipeline Diversification
- How Priovant balances development across four orphan disease indications, including non-infectious uveitis and lichen planopilaris.
Related topics